Literature DB >> 22910127

Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.

Mirjam de Roche1, Marco Siccardi, Marcel Stoeckle, Françoise Livio, David Back, Manuel Battegay, Catia Marzolini.   

Abstract

Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22910127     DOI： 10.3851/IMP2107

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  7 in total

1.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Authors:  Vincent Madelain; Minh P Le; Karen Champenois; Charlotte Charpentier; Roland Landman; Veronique Joly; Patrick Yeni; Diane Descamps; Yazdan Yazdanpanah; Gilles Peytavin
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

3.  Long-term virologic outcomes following bariatric surgery in patients with HIV.

Authors:  Steven Zivich; Margaret Cauterucci; Sara Allen; Marion Vetter; Christopher Vinnard
Journal:  Obes Res Clin Pract       Date:  2015-09-26       Impact factor: 2.288

4.  Validation of Computational Approaches for Antiretroviral Dose Optimization.

Authors:  Marco Siccardi; Laura Dickinson; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Authors:  Rajith K R Rajoli; David J Back; Steve Rannard; Caren L Freel Meyers; Charles Flexner; Andrew Owen; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

6.  Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.

Authors:  Marco Siccardi; Phillip Martin; Darren Smith; Paul Curley; Tom McDonald; Marco Giardiello; Neill Liptrott; Steve Rannard; Andrew Owen
Journal:  J Interdiscip Nanomed       Date:  2016-09-29

7.  Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection.

Authors:  Kristen L Bunnell; Arwa Aldossari; Connor Perkins; Christopher Schriever; Thomas D Chiampas; Jeremy D Young; Mahesh C Patel; Melissa Badowski
Journal:  J Int Assoc Provid AIDS Care       Date:  2018 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.